Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
32
SLN Quote, Financials, Valuation and Earnings
Last price:
$6.18
Seasonality move
:
-4.72%
Day range:
$5.99 - $6.29
52-week range:
$1.97 - $8.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
144.02x
P/B ratio:
3.92x
Volume:
159K
Avg. volume:
295.9K
1-year change:
-12.29%
Market cap:
$290M
Revenue:
$43.3M
EPS (TTM):
-$2.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLN
Silence Therapeutics Plc
|
$4.4M | -$0.21 | 2786.98% | -57.95% | $33.80 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$5M | -$0.00 | -100% | -88.64% | $7.20 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLN
Silence Therapeutics Plc
|
$6.14 | $33.80 | $290M | -- | $0.00 | 0% | 144.02x |
|
AUTL
Autolus Therapeutics Plc
|
$1.68 | $9.52 | $447.1M | -- | $0.00 | 0% | 8.72x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.87 | $17.94 | $2.4M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$2.30 | $7.20 | $365.7M | -- | $0.00 | 0% | 718.19x |
|
NCNA
NuCana Plc
|
$3.34 | $104.00 | $13.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLN
Silence Therapeutics Plc
|
0.25% | 4.841 | 0.07% | 5.88x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 0.598 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLN
Silence Therapeutics Plc
|
-$20.4K | -$23.5M | -101.95% | -102.07% | -14885.38% | -$10.8M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Silence Therapeutics Plc vs. Competitors
-
Which has Higher Returns SLN or AUTL?
Autolus Therapeutics Plc has a net margin of -13184.87% compared to Silence Therapeutics Plc's net margin of -373.3%. Silence Therapeutics Plc's return on equity of -102.07% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital SLNSilence Therapeutics Plc-12.91% -$0.44 $74.2M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About SLN or AUTL?
Silence Therapeutics Plc has a consensus price target of $33.80, signalling upside risk potential of 450.49%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 480.62%. Given that Autolus Therapeutics Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Autolus Therapeutics Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNSilence Therapeutics Plc3 0 1 AUTLAutolus Therapeutics Plc9 0 0 -
Is SLN or AUTL More Risky?
Silence Therapeutics Plc has a beta of 1.347, which suggesting that the stock is 34.727% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock SLN or AUTL?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLN or AUTL?
Silence Therapeutics Plc quarterly revenues are $158K, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Silence Therapeutics Plc's net income of -$20.8M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 144.02x versus 8.72x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNSilence Therapeutics Plc144.02x -- $158K -$20.8M AUTLAutolus Therapeutics Plc8.72x -- $21.1M -$78.6M
-
Which has Higher Returns SLN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -13184.87% compared to Silence Therapeutics Plc's net margin of --. Silence Therapeutics Plc's return on equity of -102.07% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital SLNSilence Therapeutics Plc-12.91% -$0.44 $74.2M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About SLN or BDRX?
Silence Therapeutics Plc has a consensus price target of $33.80, signalling upside risk potential of 450.49%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 5406.23%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNSilence Therapeutics Plc3 0 1 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is SLN or BDRX More Risky?
Silence Therapeutics Plc has a beta of 1.347, which suggesting that the stock is 34.727% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock SLN or BDRX?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLN or BDRX?
Silence Therapeutics Plc quarterly revenues are $158K, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Silence Therapeutics Plc's net income of -$20.8M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 144.02x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNSilence Therapeutics Plc144.02x -- $158K -$20.8M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns SLN or MREO?
Mereo BioPharma Group Plc has a net margin of -13184.87% compared to Silence Therapeutics Plc's net margin of -2923.31%. Silence Therapeutics Plc's return on equity of -102.07% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital SLNSilence Therapeutics Plc-12.91% -$0.44 $74.2M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About SLN or MREO?
Silence Therapeutics Plc has a consensus price target of $33.80, signalling upside risk potential of 450.49%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $7.20 which suggests that it could grow by 213.11%. Given that Silence Therapeutics Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe Silence Therapeutics Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNSilence Therapeutics Plc3 0 1 MREOMereo BioPharma Group Plc6 0 0 -
Is SLN or MREO More Risky?
Silence Therapeutics Plc has a beta of 1.347, which suggesting that the stock is 34.727% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.425%.
-
Which is a Better Dividend Stock SLN or MREO?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLN or MREO?
Silence Therapeutics Plc quarterly revenues are $158K, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Silence Therapeutics Plc's net income of -$20.8M is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 144.02x versus 718.19x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNSilence Therapeutics Plc144.02x -- $158K -$20.8M MREOMereo BioPharma Group Plc718.19x -- -- -$7M
-
Which has Higher Returns SLN or NCNA?
NuCana Plc has a net margin of -13184.87% compared to Silence Therapeutics Plc's net margin of --. Silence Therapeutics Plc's return on equity of -102.07% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital SLNSilence Therapeutics Plc-12.91% -$0.44 $74.2M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About SLN or NCNA?
Silence Therapeutics Plc has a consensus price target of $33.80, signalling upside risk potential of 450.49%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 622654.49%. Given that NuCana Plc has higher upside potential than Silence Therapeutics Plc, analysts believe NuCana Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNSilence Therapeutics Plc3 0 1 NCNANuCana Plc0 1 0 -
Is SLN or NCNA More Risky?
Silence Therapeutics Plc has a beta of 1.347, which suggesting that the stock is 34.727% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock SLN or NCNA?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLN or NCNA?
Silence Therapeutics Plc quarterly revenues are $158K, which are larger than NuCana Plc quarterly revenues of --. Silence Therapeutics Plc's net income of -$20.8M is lower than NuCana Plc's net income of -$378.9K. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 144.02x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNSilence Therapeutics Plc144.02x -- $158K -$20.8M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
